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ABSTRACT 
 
A specific, sensitive and rapid RP-HPLC method has been developed for the determination of Tirofiban in serum. 
The chromatographic separation was realized using reverse phase LiChrospher
®
 100 RP-18 column (4.0 mm × 250 
mm, 5 μm) and mobile phase consisting the mixture of 0.1 M KH2PO4 (pH 5.2, adjusted with 1.0 N sodium 
hydroxide solution) and acetonitrile, with the ratio of 70:30% (v/v) and flow rate of 1.0 ml/min. The detection was 
carried out at 274 nm. The response was linear over the range of 0.03 – 0.18 mgmL-1 in mobile phase and serum 
samples. The limit of detection (LOD) for Tirofiban was 1.84, 13.8 and 14.6 μg mL-1 in methanol, spiked rat serum 
and spiked human serum, respectively. The described method can be quickly and routinely applied, without any 
interference from endogenous substances, for therapeutic monitoring of levels of Tirofiban in the serum samples. 
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INTRODUCTION 
 
Tirofiban hydrochloride, a non-peptide antagonist of 
fibrinogen binding the platelet glycoprotein (GP) 
IIb/IIIa receptor and inhibits platelet aggregation. 
Tirofiban hydrochloride monohydrate is chemically 
described as a N-(butylsulfonyl)-O-(4-[4-piperidinyl] 
butyl)-L-tyrosine monohydrochloride monohydrate 
(Figure 1.). The empirical formula of Tirofiban is 
C22H36N2O5S·HCl·H2O and molecular weight of 
495.08. 
[1,2]
.  
Tirofiban can be used in combination with heparin 
and aspirin in the treatment of patients with unstable 
angina or non-Q-wave myocardial infarction, 
including patients under subsequently percutaneous 
transluminal coronary angioplasty (PTCA)
 [3,4]
.  
Adjunctive therapy with a GP IIb/IIIa-receptor 
inhibitors can reduce the incidence of cardiac 
ischemic events, including subsequent myocardial 
infarction (MI) and death, in the patients with non-
ST-segment-elevation acute coronary syndromes 
[5,6]
 
Tirofibanprescribed and administrated to the patient 
according to the recommended treatment, attain more 
than 90% inhibition by the end of the 30-minute 
infusion. Platelet aggregation inhibition is reversible 
following cessation of the infusion of Tirofiban. 
Tirofiban with a half-life of approximately 2 hours 
[2]
 
is not strongly bound to plasma protein. Protein 
binding of Tirofibanis concentration-independent in 
the range of 0.01–25 μgmL-1. The unbound fraction 
in human plasma is around 35% and the distribution 
volume of Tirofiban in the steady state is about 30 
liters.  
Experiments with 
14
C-labelled Tirofiban
[7-9] 
showthat 
the radioactivity in urine and feces is emitted chiefly 
by unchanged Tirofiban. The radioactivity in 
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circulating plasma originates is mainly from 
unchanged Tirofiban (up to 10 hours after 
administration). These data present limited 
metabolism of Tirofiban. After intravenous 
administration of 
14
C-labelled Tirofiban to the 
healthy subjects, 66% of the radioactivity was 
recovered in the urine, 23% in the feces. The total 
recovery of radioactivity is 91%. Renal and biliary 
excretion contributes significantly to the elimination 
of Tirofiban. )
[7-9]
 
Very few methods for the examination of 
Tirofibanwho use biological samples have been 
reported. 
[10,11]
, The direct determination of Tirofiban 
using UV detector to carry out pharmacokinetic 
parameters of Tirofiban, have not yet been 
described.. For the determination of Tirofiban in 
pharmaceutical dosage formulation for routine 
analysis and in a pure substance form, only a few 
HPLC methods were used. 
[14, 15]
 
The purpose of this paper is to describe the 
development of reliable, reproducible, fully 
validated, easy to perform, and low cost routine RP-
HPLC method for the determination of Tirofiban in 
serum samples. The method appears to be suitable for 
the therapeutic monitoring of the levels of Tirofiban 
in serum samples. 
 
MATERIAL AND METHODS 
 
Apparatus and Chromatographic Conditions: The 
sample analyses were performed usingHPLC system 
(Perkin Elmer Series 200), containing tertiary pump, 
UV / VIS detector and auto sampler. The separation 
was carried out in the room temperature, using 
reversed-phase LiChrospher
®
 100 RP-18 column (4.0 
mm × 250 mm, 5 μmparticle size). The 
chromatographic separation was performed using an 
isocraticmethod. The mobile phase contained a 
mixture of 0.1 M KH2PO4 (pH 5.2, adjusted with 1.0 
N sodium hydroxide solution) and acetonitrile in the 
ratio 70:30 % v/v and flow rate of 1.0 ml min
-1
. The 
UV detector was set at a wavelength of 274 nm. The 
injection volume of samples was 50 µl.  
 
Chemicals and Reagents: Tirofiban hydrochloride 
as a Reference Standard was supplied from Merck 
(batch No. L-000700462-006X027). Methanol and 
acetonitrile with HPLC grade were provided from 
Sigma Aldrich. All other chemicals were with 
analytical reagent grade. Redistilled water was used 
to prepare solutions for mobile phase. 
 
Standard Solutions and Calibration Curves: The 
standard stock solution of Tirofiban was prepared by 
dissolving 10 mg of Tirofiban hydrochloride with 50 
mL of methanol in a 50 mL volumetric flask. After 
suitable dilutions (1,5 ml; 3 ml; 4,5 ml; 6 ml; 7,5 ml 
and 9 ml of standard stock solution up to 10 ml with 
methanol in a 10 ml volumetric flask) the 
concentration of Tirofiban was varied in the range of 
0,03–0,18 mgmL-1. The calibration curve for HPLC 
analysis was constructed by plotting the ratio of the 
peak area of the drug against the drug concentration. 
All solvents and solutions for HPLC analysis were 
filtered using a membrane filter (0.45 μm pore size) 
and vacuum degassed before use. 
 
Validation of the Method: The precision and 
reproducibility were checked for the period ofseveral 
days; both within day (n = 5) and between days (n = 
5) for two different concentrations. Relative standard 
deviations were calculated to obtain the ruggedness 
and precision of the method. The precision and 
reproducibility of the proposed method 
wereevaluated by performing replicate analysis of the 
standard solutions. Two different concentrations 
within calibration range were prepared in methanol 
and serum samples, and analyzed with related 
calibration curves to determine intra-day and inter-
day variability. 
 
Recovery Studies: In order to establish the accuracy 
and reliability of the proposed method, recovery 
experiments were carried out by the standard addition 
method. The known amounts of the standard solution 
of Tirofiban were added to the rat and the human 
serum, mixed and analyzed by the proposed method. 
After five repeated experiments, the recoveries were 
calculated. 
 
Recovery Studies in Spiked Human and Rat 
Serum Samples: The reason that serum samples 
were used for this study and collected from the 
normal human volunteers and from the normal rat 
before introducing the experimental model of deep 
venous thrombosis (DVT) was to obtain validated 
quantitative method appropriate to follow the 
concentration of Tirofiban and potential various 
degradation products in vitro and in vivo after 
application. 
Aliquots of 1 ml human and rat serum samples were 
spiked with 30 µl, 60 µl, 90 µl, 120 µl, 150 µl and 
180 µl of Tirofiban standard solution with 
concentration of 3 mg mL
-1
. The heparin as an 
anticoagulant was added. After heating on water bath 
for 15 min., the tubes were centrifuged for 5 min at 
3500 rpm min
-1
. The supernatant was taken carefully, 
methanol was added for precipitation of proteins in 
ratio serum : methanol = 1:3 and then the tubes were 
centrifuged again for 5 min at 3500 rpm min
-1
. The 
supernatant was taken carefully. The concentration of 
Tirofiban was varied in the range of 0.03–0.18mgmL-
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1
. Serum samples were injected into the HPLC 
column. The amount of Tirofiban in spiked human 
and rat serum samples was calculated from the 
related linear regression equation. 
 
Limit of Detection and Limit of Quantification: 
The limit of detection (LOD) and limit of 
quantitation (LOQ) was calculated using following 
formulae: LOD = 3.3 SD/S and LOQ = 10 SD/S,, 
where SD is the standard deviation of the response 
(peak area) and S is the slope of the calibration curve 
obtained. 
 
RESULTS AND DISCUSSION 
 
Initial experiments were carried out using the mobile 
phase consisting of phosphate buffer and acetonitrile 
in different proportions and at different pH values. 
Mobile phase composition of 0.1 M KH2PO4 (pH 5.2, 
adjusted with 1.0 N sodium hydroxide solution) and 
acetonitrile (70:30, v/v) was finally optimized to give 
retention time of 8.6 min and 12.9 min. for Tirofiban 
and heparin, respectively. This mobile phase 
composition was found to be optimal for good peak 
resolution. The optimum wavelength for detection 
was 274 nm, at which the best detector response was 
obtained for Tirofiban. 
 
System suitability tests should be an integral part of 
each analytical HPLC methods.
[12,13] 
and in our study 
was performed through evaluation of different 
parameters (retention time, tailing factor, capacity 
factor, resolution, and selectivity). System suitability 
tests were carried out on freshly prepared standard 
stock solutions of Tirofiban. Tailing and capacity 
factors were obtained as 1.17 and 2.41 for Tirofiban. 
Resolution factor for this system for Tirofiban and 
heparin was 3.90. The retention times of Tirofiban in 
methanol, human and rat serum samples were 9.1, 
9.2, and 9.16 min, respectively. The variation in 
retention time of Tirofiban among five replicate 
injections of standard solution in methanol, human 
and rat serum samples was very slight, giving the 
relative standard deviations (RSD%) of  0.61%, 
0.93%, and 0.82%, respectively.  
 
Linearity of response was studied by running the 
standard curve of Tirofiban. The plot of peak area 
ratio vs.Tirofiban concentration in methanol and 
spiked serum samples was linear in the concentration 
range of 0.03 – 0.18 mgmL-1. The determination 
coefficient was greater than 0.99 for both media. 
Table 1 shows the calibration characteristics and 
validation parameters of Tirofiban. 
The intra and inter-day precision was determined as 
the RSD%. Precision, accuracy, and reproducibility 
results shown in Table 2 demonstrate good precision, 
accuracy, and reproducibility. 
 
The stability studies of Tirofiban in methanol 
indicated no significant changes in sample 
concentrations after storage of samples in the period 
of 72 hours at 4
o
C in refrigerator. 
 
Based on the obtained results, the proposed method 
was applied for the direct determination of Tirofiban 
content in the serum.  
 
In order to check the applicability of the proposed 
method to the human and rat serum samples, the 
linearity range studies and recovery studies were 
performed.  Calibration graph parameters are the 
same as showed in Table 1. Required validation 
parameters and recovery study results for human and 
rat serum samples are given in Table 2 and Table 3.  
The Figure 2ashows a typical chromatogram of the 
extract of the fresh blank serum sample, while Figure 
2c and Figure 2d show chromatograms obtained 
when the same method was applied to spiked human 
and rat serum samples. There are no anyextraneous 
peaks from endogenous substances in chromatograms 
obtained in serum samples.   
 
CONCLUSION 
 
The proposed RP-HPLC method is a simple, 
accurate, precise and rapid for the determination of 
Tirofiban in the serum and for monitoring its 
concentration in serum. The developed HPLC 
method was fully validated by evaluation of the 
validation parameters. The proposed method use the 
simple serum deproteinization step instead of 
extraction. No interferences from endogenous 
substances in serum samples. High percentage of 
recovery shows that the method is free from the 
interferences from endogenous substances observed 
in serum samples. Our results confirmed our aim, to 
shows the possibility to follow this drug during the 
therapyand have in a same time the method useful for 
the pharmacokinetic and pharmacodynamic 
evaluation of Tirofiban given alone or in the presence 
of Heparin and Aspirin as simultaneous therapy. The 
obtained results show that the proposed method can 
be useful also to determine Tirofiban in human serum 
in the levels obtained after the administration of 
normal therapeutic dose. 
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Figure 1. Chemical structure of Tirofiban hydrochloride. 
 
 
Figure 2a. Chromatogram of blank serum 
 
 
Figure 2b. Chromatogram of methanol used as solvent 
 
Figure 2c. Chromatogram of Tirofiban in methanol (0,0675 mg mL
-1
) 
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Figure 2d. Chromatogram of Tirofiban (0,0675 mg mL
-1
) and heparin (12500 I.U mL
-1
) in methanol 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2e. Chromatogram of serum spiked with Tirofiban (0,0337 mg mL
-1
) and heparin (12500 I.U mL
-1
) 
 
 
Table 1.  Characteristics of the linear regression analysis of Tirofiban 
 Methanol Human Serum  Rat serum 
Linearity range (mgmL
-1
) 0.03–0.18 0.03–0.18 0.03 -0.18 
Slope 9200223 7942560 8795042 
Intercept 2720.6 90750 23999 
Determination coefficient (r
2
) 
0.9999 0.9943 
0.9949 
SE
a
 of the intercept 5124.18 35082.2 36834.2 
SE of the slope 43858.91 300276.9 315271.9 
Detection limit (mgmL
-
)                            0.0018 0.0146 0.0138 
Quantification limit (mgmL
-
)                     0.0056 0.0442 0.0419 
a
SE – Standard error 
 
Table 2. Intra-day and inter-day precision of Tirofiban standards. 
 In methanol In rat serum  
Theoretical 
concentration 
(mg mL
-1
) 
Intra-day measured 
concentration 
(mg mL
-1
)
a
 
Inter-day measured 
concentration 
(mg mL
-1
)
b
 
Intra-day measured 
concentration 
(mg mL
-1
)
a
 
Inter-day measured 
concentration 
(mg mL
-1
)
b
 
 Mean RSD% Mean RSD% Mean RSD% Mean RSD% 
0.06 0.0577 1.15 0.0564 1.27 0.0562 1.72 0.0573 1.55 
0.15 0.1484 0.93 0.1475 1.33 0.1462 1.39 0.1458 1.91 
a
Each value was obtained from five different Tirofiban standards on the same day 
b
 Between-day reproducibility was determined from five different runs over a two weeks period 
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Table 3. Results of the assay and the recovery analysis of Tirofiban 
Parameter Rat serum samples  
(mgmL
-1
) 
Human serum samples 
(mgmL
-1
) 
Added      0.90 0.12 
Recovered
a
 0.8875 0.1143 
Recovery (%)                                         98.61 95.25 
RSD of recovery (% ) 1.23 1.87 
a
 Mean value of 5 determinations 
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